Lixte Biotechnology Holdings, Inc.
LIXT
$4.86
-$0.01-0.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.40% | -34.00% | -30.29% | -35.74% | -28.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.89% | -40.20% | -3.99% | -39.57% | -29.43% |
| Operating Income | 26.89% | 40.20% | 3.99% | 39.57% | 29.43% |
| Income Before Tax | 26.94% | 40.16% | 3.22% | 39.41% | 28.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.94% | 40.16% | 3.22% | 39.41% | 28.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.94% | 40.16% | 3.22% | 39.41% | 28.98% |
| EBIT | 26.89% | 40.20% | 3.99% | 39.57% | 29.43% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 33.51% | 40.07% | 10.71% | 55.12% | 47.43% |
| Normalized Basic EPS | 33.53% | 40.08% | 10.72% | 55.12% | 47.43% |
| EPS Diluted | 33.51% | 40.07% | 10.71% | 55.12% | 47.43% |
| Normalized Diluted EPS | 33.53% | 40.08% | 10.72% | 55.12% | 47.43% |
| Average Basic Shares Outstanding | 9.88% | -0.16% | 8.41% | 35.01% | 35.09% |
| Average Diluted Shares Outstanding | 9.88% | -0.16% | 8.41% | 35.01% | 35.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |